Moleculin Biotech Inc.

0.86
-0.10 (-10.51%)
At close: Apr 03, 2025, 3:59 PM
0.89
3.77%
After-hours: Apr 03, 2025, 07:51 PM EDT

Company Description

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses.

Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.

The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies.

It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19.

The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.

Moleculin Biotech Inc.
Moleculin Biotech Inc. logo
Country United States
IPO Date Jun 2, 2016
Industry Biotechnology
Sector Healthcare
Employees 17
CEO Walter V. Klemp

Contact Details

Address:
5300 Memorial Drive
Houston, Texas
United States
Website https://www.moleculin.com

Stock Details

Ticker Symbol MBRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001659617
CUSIP Number 60855D309
ISIN Number US60855D3098
Employer ID 47-4671999
SIC Code 2834

Key Executives

Name Position
Walter V. Klemp Co-Founder, Chairman, President & Chief Executive Officer
Jonathan P. Foster CPA Executive Vice President & Chief Financial Officer
Dr. Donald H. Picker Ph.D. Chief Scientific Officer
Dr. John Paul Waymack M.D., Sc.D. Senior Chief Medical Officer
Dr. Waldemar Priebe Ph.D. Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board

Latest SEC Filings

Date Type Title
Apr 01, 2025 8-K Current Report
Mar 31, 2025 S-1 Filing
Mar 24, 2025 8-K Current Report
Mar 24, 2025 8-K Current Report
Mar 21, 2025 10-K Annual Report
Mar 13, 2025 DEF 14A Filing
Mar 06, 2025 8-K Current Report
Mar 03, 2025 PRE 14A Filing
Feb 26, 2025 8-K Current Report
Feb 26, 2025 424B5 Filing